Xenon Pharmaceuticals has voluntarily paused enrollment in its phase 3 depression trials after patients experienced psychosis-related adverse events. The company said the events were mostly mild or moderate in severity, but the decision to halt new enrollment signals a notable safety concern.
The news rattled investors, with shares falling as the "neuropsychiatric" events fueled doubts about the drug's prospects. The setback is especially significant because the same therapy, azetukalner, is already under review by the FDA for a form of epilepsy, giving the safety signal broader regulatory implications.
Both sources agree on the core facts: the pause was voluntary and stemmed from adverse events in the depression studies. They differ in emphasis, with one source highlighting the company's characterization of the events as mostly mild or moderate, while the other focuses on the market reaction and the drug's pending epilepsy review.